ReviewInternational journal of molecular sciences2016
The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- The Need for a Systems Biology Approach in Cancer Explained.International journal of molecular sciences · 2025Review
- Therapeutic Colorectal Cancer Vaccines: Emerging Modalities and Translational Opportunities.Vaccines · 2025Review
- Article
- Construction of a prognostic model for colorectal cancer liver metastasis based on single-cell transcriptomics and regulation of the MIF pathway.Frontiers in oncology · 2025Article
- Characterizing macrophage diversity in colorectal malignancies through single-cell genomics.Frontiers in immunology · 2025Review
- High tumor mutational burden assessed through next-generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients.Journal of translational medicine · 2024Article
- Expanded Alternatives of CRISPR-Cas9 Applications in Immunotherapy of Colorectal Cancer.Molecular diagnosis & therapy · 2024Review
- Dynamics of the immune microenvironment and immune cell PANoptosis in colorectal cancer: recent advances and insights.Frontiers in immunology · 2024Review
- Dendritic cells transfected with a polyepitope DNA construct stimulate an antitumor cytotoxic response in various tumors.Molecular and clinical oncology · 2022Article
- Calf Thymus Polypeptide Restrains the Growth of Colorectal TumorFrontiers in pharmacology · 2022Article
- From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer.Journal of inflammation research · 2022Review
- Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development.The Journal of clinical investigation · 2021Article
- Immune System, Microbiota, and Microbial Metabolites: The Unresolved Triad in Colorectal Cancer Microenvironment.Frontiers in immunology · 2021Review
- Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis.Oncoimmunology · 2020Article
- Review
- Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer.The pharmacogenomics journal · 2020Review
- Construction of an Immunogenomic Risk Score for Prognostication in Colon Cancer.Frontiers in genetics · 2020Article
- Chemo-immunotherapy of colon cancer with focused ultrasound and Salmonella-laden temperature sensitive liposomes (thermobots).Scientific reports · 2018Article
- Strategy to targeting the immune resistance and novel therapy in colorectal cancer.Cancer medicine · 2018Review
- Early and Partial Reduction in CD4Journal of Cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although most cancer types have been viewed as immunologically silent until recently, it has become increasingly clear that the immune system plays key roles in the course of tumor development. Remarkable progress towards understanding cancer immunogenicity and tumor-immune system interactions has revealed important implications for the design of novel immune-based therapies. Natural immune responses, but also therapeutic interventions, can modulate the tumor phenotype due to selective outgrowth of resistant subtypes. This is the result of heterogeneity of tumors, with genetic instability as a driving force, and obviously changes the immunogenicity of tumors. In this review, we discuss the immunogenicity of colorectal cancer (CRC) in relation to tumor development and treatment. As most tumors, CRC activates the immune system in various ways, and is also capable of escaping recognition and elimination by the immune system. Tumor-immune system interactions underlie the balance between immune control and immune escape, and may differ in primary tumors, in the circulation, and in liver metastases of CRC. Since CRC immunogenicity varies between tumors and individuals, novel immune-based therapeutic strategies should not only anticipate the molecular profile, but also the immunological profile of a specific tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.